333 related articles for article (PubMed ID: 27798797)
1. Many Miles to Go: A Systematic Review of the State of Cost-Utility Analyses in Brazil.
Campolina AG; Rozman LM; Decimoni TC; Leandro R; Novaes HM; De Soárez PC
Appl Health Econ Health Policy; 2017 Apr; 15(2):163-172. PubMed ID: 27798797
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review of Health Economic Evaluation Studies Developed in Brazil from 1980 to 2013.
Decimoni TC; Leandro R; Rozman LM; Craig D; Iglesias CP; Novaes HMD; de Soárez PC
Front Public Health; 2018; 6():52. PubMed ID: 29541630
[TBL] [Abstract][Full Text] [Related]
3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
4. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.
Augustovski F; Iglesias C; Manca A; Drummond M; Rubinstein A; Martí SG
Pharmacoeconomics; 2009; 27(11):919-29. PubMed ID: 19888792
[TBL] [Abstract][Full Text] [Related]
5. Trends in the measurement of health utilities in published cost-utility analyses.
Brauer CA; Rosen AB; Greenberg D; Neumann PJ
Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.
Han R; François C; Toumi M
Appl Health Econ Health Policy; 2021 Jan; 19(1):29-44. PubMed ID: 32661846
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
8. The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.
Sonntag M; König HH; Konnopka A
Pharmacoeconomics; 2013 Dec; 31(12):1131-54. PubMed ID: 24293216
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluations in gastroenterology in Brazil: A systematic review.
de Paiva Haddad LB; Decimoni TC; Turri JA; Leandro R; de Soárez PC
World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):162-70. PubMed ID: 26855823
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of health economic evaluation studies of dengue vaccines.
de Soárez PC; Silva AB; Randi BA; Azevedo LM; Novaes HMD; Sartori AMC
Vaccine; 2019 Apr; 37(17):2298-2310. PubMed ID: 30910406
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analyses of drug therapies in breast cancer: a systematic review.
Nerich V; Saing S; Gamper EM; Kemmler G; Daval F; Pivot X; Holzner B
Breast Cancer Res Treat; 2016 Oct; 159(3):407-24. PubMed ID: 27572551
[TBL] [Abstract][Full Text] [Related]
13. Are adverse effects incorporated in economic models? An initial review of current practice.
Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
[TBL] [Abstract][Full Text] [Related]
14. Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?
Defourny N; Monten C; Grau C; Lievens Y; Perrier L
Radiother Oncol; 2019 Dec; 141():14-26. PubMed ID: 31630866
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
16. The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.
Rodriguez JM; Paz S; Lizan L; Gonzalez P
Value Health; 2011 Jun; 14(4):458-64. PubMed ID: 21669370
[TBL] [Abstract][Full Text] [Related]
17. Application of classic utilities to published pediatric cost-utility studies.
Finnell SM; Carroll AE; Downs SM
Acad Pediatr; 2012; 12(3):219-28. PubMed ID: 22075466
[TBL] [Abstract][Full Text] [Related]
18. The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies.
de Soarez PC; Martins Rozman L; Siraisi Fonseca T; Rodrigo Borsari P; Percio J; Guzmán Barrera LS; Christovam Sartori AM
Vaccine; 2023 Feb; 41(7):1319-1332. PubMed ID: 36707337
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
